Overall, these data suggest that IL-23-driven T-cell responses are critically contributing to the manifestation of intestinal inflammation both in murine syngeneic colitis models and in human IBD and hence Th17-centered concepts are highly promising to provide progress for the therapy of IBD in the future. This evidence concerns the gene IL37 and inflammatory bowel disease.